1. Introduction {#s0005}
===============

Immunization with effective vaccines brings immense value to children, families, communities and economies [@b0005], [@b0010], [@b0015]. Vaccines are one of the greatest medical advances of modern times [@b0020], [@b0025]. Millions of lives have been saved yearly and some of the Region's biggest child killers, ranging from measles and diphtheria to pneumococcal disease and diarrhoea cases due to rotavirus have been drastically reduced [@b0030], [@b0035]. The benefits of vaccinating children go beyond saving their lives and extend to protecting their education, returning precious time and money to their families and making critical investments in future prosperity [@b0015]. As reflected in the *WHO Immunization Business Case for the African Continent*, apart from contributing heavily to child mortality, four major vaccine preventable diseases (VPDs), namely pneumococcal diseases, rotavirus, measles and rubella, impose significant economic impacts on countries estimated at approximately US\$13 billion annually [@b0040]. Thus, the importance of achieving and sustaining immunization targets across all countries in terms of VPD control, elimination and eradication, the successful introduction of new vaccines, attainment of high and equitable levels of coverage, and management of VPD outbreaks cannot be over-emphasized.

While tremendous progress has been made towards reaching every child, a lot remains to be done: the most recent available data demonstrates that immunization coverage in the 10 middle-income countries (MICs) in the WHO African Region is decreasing [@b0045]. The 2017 WHO and UNICEF estimates of national immunization coverage indicates that 527 052 children in these MICs did not receive their 3rd dose of DPT in 2016. This represents one out of four children of their birth cohort and the average coverage dropped from 83% in 2015 to 77% in 2017 [@b0050]. Several of these countries would like to introduce new vaccines, yet they are facing prohibitive prices. Beyond the issues of high vaccine cost, there are also issues with lack of technical capacity on forecasting and planning, unreliability of local vaccine suppliers, limited and unpredictable funding. As new vaccines are becoming available more countries are making efforts to introduce them. However, these new vaccines are more expensive and the benefits are denied to populations in the non-eligible countries and those graduating out of Gavi support have a serious challenge ahead to attain universal immunization coverage under.

Though, WHO/AFRO is committed to addressing this issue, success for such an initiative can only rely heavily on strong, steady political commitment from all levels of government. The political commitment needed to advance immunization goals in the Region is being harnessed: at the Ministerial Conference on Immunization in Africa held in 2016, Ministers of Health and other line ministers launched the Addis Declaration on Immunization (ADI) to spur greater political and financial commitments to immunization. On 31 January 2017, this commitment was echoed by the highest level of government when Heads-of-State from across Africa endorsed the ADI at the 28th African Union Summit in Addis Ababa. In August 2017, during the 67th session of WHO/AFRO Regional Committee meeting, Ministers of Health requested WHO's support to access affordable vaccines for middle-income countries and those transitioning out of Gavi support.

Against this backdrop, WHO/AFRO convened a three day consultative meeting between 9 and 11 April 2018 to undertake an in-depth review of country situation in relation to sustainable access to timely and affordable vaccines as well as share country experiences with a focus on evidence-based decision-making, financing and procurement processes. Participants deliberated on the feasibility of vaccine procurement and funding options and on defining region-wide priorities to tackle the challenge of the MICs.

Participants were drawn from 17 low, middle and upper middle income countries in the African Region sharing their experiences and concerns and proposing solutions. Peer support was encouraged through sharing of progress and lessons learnt by other regions, namely other WHO Regions (Eastern and Mediterranean Region \[EMRO\], Europe Region \[EURO\] and Pan American Region \[PAHO\]). Representatives of immunization partners such as BMGF, CHAI, Gavi, Global Health, GSK, JSI, MSF, PATH, UNICEF, the US Center for Disease Prevention, and Control (CDC), Results for Development among others also shared their perspectives on vaccine procurement and access to vaccines for MICs. The programme included plenary presentations, discussion and group work to identify potential solutions to the different challenges of accessing vaccine in MICs in the African Region. It was hoped that by the end of the meeting participants would understand and be more engaged on how African middle-income country challenges differ from those from other regions. As most economies face periodic contraction, thereby constraining the government fiscal environment, the suggestions of participants on possible efficiencies in procurement systems including pool procurement platforms were also solicited.

This paper summarizes the proceedings of the first WHO/AFRO consultative meeting aimed at improving access to affordable vaccines for MICs in the African Region and proposed steps to tackle the challenges to achieving universal and equitable access to effective vaccines. This keeps with the ethical and moral obligation to guarantee the life of all future generation through access to life-saving vaccine in Africa [@b0055].

2. Middle income country strategy and country experiences {#s0010}
=========================================================

Much remains to be done if GVAP targets are to be met as non-Gavi MICs represent almost 40% of PCV-3 unimmunized children [@b0060]. The majority of MICs do not receive external financial support for immunization and data reveals that national financial resources for immunization are growing at a much slower rate than in countries outside of this group. Review of publicly available pricing data from WHO Market Information for Access Initiative (MI4A) revealed that non-Gavi MICs pay considerably higher prices than lower-income countries for several vaccines and vaccine price differentiation within non-Gavi MICs is large and not transparently explained - [Fig. 1](#f0005){ref-type="fig"} [@b0065]. The challenges facing non-Gavi MICs and Gavi-graduating countries, including those in the African Region, are addressed in a Middle-Income Country Strategy developed by WHO and partners and endorsed by the WHO's Strategic Advisory Group of Expert on Immunization (SAGE) in 2015[@b0070]. The strategy aims to coordinate partner action against four key areas identified by countries -- namely: improving access to affordable & timely supply of vaccines; strengthening decision-making; increasing political commitment & financial sustainability; and enhancing demand for and equitable delivery of vaccines. Despite widespread agreement on the Strategy pillars and proposed actions, immunization partners have, till date, struggled to mobilize adequately funding for full-scale implementation.Fig. 1Comparative prices for vaccines in different categories of countries.

3. Experiences of countries on accessing affordable vaccines {#s0015}
============================================================

The countries highlighted a number of challenges they face in accessing affordable vaccines to include unpredictability in timeliness in cash disbursements for procurement; increasing co-financing contribution within a tight resource envelope expected with accelerated transition from Gavi support; inadequate availability of some vaccines in the global market to meet the demand; and inadequate storage capacity for current and planned new vaccines introductions necessitating an average of 180 shipments per annum (see [Fig. 2](#f0010){ref-type="fig"}). One concrete example came from Namibia, where the introduction of HPV vaccine was delayed due to funding challenges and cost of the vaccine.Fig. 2National trend of OPV3/Penta 3, PCV3, Rota 2 and MCV coverage 2012--2017 in Namibia.

Procurement processes for Namibia and eSwatini were explained, as case in point, focusing on challenges with quantification, tendering process, vendor selection and price of vaccines. This resulted in a downward trend in the coverage with some specific vaccines. Beyond the issues of high vaccine cost, there are also issues with lack of technical capacity on forecasting and planning, unreliability of local vaccine suppliers, as well as absence of vaccine manufacturing entities in those countries. Furthermore, there is a strict requirement of upfront payment for countries to access cost saving benefits in using UNICEF procurement platform. The Namibian presentation also listed issues with distribution of vaccine, using the pooling system and sporadic expiration of vaccine due to overstock in some areas and short shelf-life as well as stock-outs as factors responsible for poor vaccine coverage witnessed in recent years. Key questions, here, were on the sustainability of resource mobilization efforts for immunization: these seem to be ad hoc and not institutionalized. In particular, the issue of immunization legislation and engagement with parliamentarians was discussed.

Participants from Angola highlighted the strategies currently being implemented to ensure immunization targets are attained to include strengthening the cold-chain & logistics system, improving data quality, community engagement, among others. [Fig. 3](#f0015){ref-type="fig"} revealed that coverage is declining both on administrative and WHO UNICEF coverage estimates. Some key challenges faced in the country were listed to include sustaining immunization coverage post transition as well as ensuring regular access to vaccines and having a system in place to collect vaccines/immunization data from the private healthcare sector.Fig. 3[Fig. 1](#f0005){ref-type="fig"}: Trend in coverage of Penta 3 in Angola (2010--2017).

4. Experiences from other regions in access to affordable vaccines {#s0020}
==================================================================

The presentations on EURO show that the situation varies from one country to another depending on the level of income as well. Middle income countries account for 68.5 percent of unvaccinated children. The presentation on the situation in the EMRO is characterized by a strong commitment on vaccination. Nevertheless, countries have experienced long delays in the introduction of new vaccines due to high prices and insufficient resources, competing priorities and lack of regulation between the public and the private sector, aside for persistent conflict in several areas. The PAHO focused on the contribution of the Revolving Fund, created since 1977, in ensuring vaccine security. The discussions focused on the solidarity among countries despite their diversity, the harmonization of legislation and regulatory frameworks.

5. Registration, legislation and financing for vaccines in MICs {#s0025}
===============================================================

The concern, here, was on the sustainability of resource mobilization efforts for immunization: these seem to be ad hoc and not institutionalized. Countries seem to miss the necessary processes and tools to regularly engage in lobbying for increasing fiscal space for immunization as well as for expanding the health budget. Industry representatives actively engaged in discussion confirming the increased interest in MICs as the vaccine market for the future and the willingness to engage in discussion; key to this engagement is consolidated, credible and longer term demand.

Other elements discussed were the importance for countries raising concerns on legislative and financing matters in high level, and the importance of peer pressure and high level advocacy efforts to trigger political commitment and financing. On the regulatory and procurement side, issues of internal linkages and coordination across different departments were raised as well as progress on streamlining of regulatory practices, reliance on other stringent regulatory authorities and the creation of regional regulatory networks such as The African Vaccine Regulatory Forum (AVAREF) and Africa Medicines Association (AMA).

6. Partners' contribution to increase access to affordable vaccines for MICs {#s0030}
============================================================================

WHO is supporting MICs to ensure access to vaccines at affordable prices. It has identified the following six key interventions under the MIC strategy, namely: supporting MICs in increasing price/procurement/market information; influencing market dynamics through its fair pricing an access programmes; and increasing procurement skills and knowledge by its affordability and budget impact analysis and negotiating skills training. One hundred and forty-four countries, including 90% of self-procuring MICs) have collaborated with WHO on information sharing to increase price transparency (see [Fig. 4](#f0020){ref-type="fig"}). This global initiative includes information sharing on vaccines (including volumes), suppliers and prices. Furthermore, WHO is enlarging this knowledge hub with additional partner/industry sources of information. WHO prequalification of vaccines is a service provided to UN purchasing agencies by WHO to assess the quality.Fig. 4Number of countries reporting price and procurement data by WHO region over time.

Another support available is the Vaccine Independence Initiative (VII) presented by UNICEF, which is used in cases of delayed self-funded country disbursement, or delayed multi-lateral arrangement (e.g., World Bank loan) when retroactivity funding exists or is confirmed. This is a form of financing buffer that allows countries to pay after delivery of vaccines to them. For countries wishing to use the VII platform, an exit plan from VII needs to be devised from the beginning addressing the root causes of funding gaps and cash flow timing issues, through enhancing forecasting and other technical work, as well as explore the use of commercial financing instruments.

The Gavi presentation highlighted some of the important lessons learnt to date for a successful transition to include: financial and programmatic sustainability; the importance of early engagement and planning in addressing health systems bottlenecks and institutional constraints; getting the immunization basics right (i.e planning, budgeting, disbursement and execution); and prioritization of health within the overall health budget.

7. Key recommendations {#s0035}
======================

Following three days of presentations, the meeting came up with the following key recommendations.

Enhance political commitment and national funding for immunization in MICs•Ensure high level monitoring of implementation of the Addis Declaration on Immunization (ADI) by African ministries, with a dedicated focus on MICs for action towards enhanced and sustainable national funding for immunization•Leverage available regional cooperation mechanisms (for example Regional Economic Committees) to advance peer collaboration and partner engagement•Continue to provide technical support to prepare countries to be able to absorb increasing co-financing commitments as they transition out of Gavi support•Evaluate the quality of MICs decision making processes to understand and act upon key gaps

Enhance procurement and regulatory processes for vaccine availability and affordability in MICs•Improve use of now largely available price and market information to countries through the Market Information for Access (MI4A) initiative•Improve procurement skills and knowledge in countries through existing peer platforms, targeted technical assistance, skill transfer by UN agencies (e.g. PAHO RF and UNICEF SD)•Enhance demand forecasting and consolidation mechanisms among MICs in the region to better influence market dynamics and enhance access to affordable vaccines.•Explore the opportunity of different African countries coming together through Regional Economic Committees (for example, SADC and Small Island States) to immediately start efforts to strengthen and consolidate access to affordable vaccines.•Continue investing in regulatory strengthening, coordination and reliance on efforts to ensure timely access to vaccines and strengthen the immunization financing agenda in countries
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